Drug R&D crisis won't be solved by huge bonuses for scientists

08/13/2013 | Xconomy

Giving scientists in the biotech and pharmaceutical industry huge bonuses for developing blockbuster treatments, as GlaxoSmithKline is planning to do, won't fix drug research and development, Luke Timmerman writes. As much as hard-working scientists deserve the recognition and money, too many people play integral roles in the advances behind drug discoveries and it will be difficult to divide the rewards, he writes. And a system of huge payoffs for a few could increase secretiveness and risk-taking, he writes.

View Full Article in:

Xconomy

Published in Brief: